Page last updated: 2024-10-27

flumazenil and Anti-Phospholipid Antibody Syndrome

flumazenil has been researched along with Anti-Phospholipid Antibody Syndrome in 1 studies

Flumazenil: A potent benzodiazepine receptor antagonist. Since it reverses the sedative and other actions of benzodiazepines, it has been suggested as an antidote to benzodiazepine overdoses.
flumazenil : An organic heterotricyclic compound that is 5,6-dihydro-4H-imidazo[1,5-a][1,4]benzodiazepine which is substituted at positions 3, 5, 6, and 8 by ethoxycarbonyl, methyl, oxo, and fluoro groups, respectively. It is used as an antidote to benzodiazepine overdose.

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Manzano-Gamero, V1
Pardo-Cabello, AJ1
Vargas-Hitos, JA1
Zamora-Pasadas, M1
Navarrete-Navarrete, N1
Sabio, JM1
Jáimez-Gámiz, L1
Ríos-Fernandez, R1
Ortego-Centeno, N1
Ayala-Gutierrez, MM1
de Ramón, E1
Colodro-Ruíz, A1
Micó-Giner, L1
Castillo-Palma, MJ1
Robles-Marhuenda, Á1
Luna-Del Castillo, JD1
Jiménez-Alonso, J1

Other Studies

1 other study available for flumazenil and Anti-Phospholipid Antibody Syndrome

ArticleYear
Effect of ethnicity on clinical presentation and risk of antiphospholipid syndrome in Roma and Caucasian patients with systemic lupus erythematosus: a multicenter cross-sectional study.
    International journal of rheumatic diseases, 2018, Volume: 21, Issue:11

    Topics: Abortion, Spontaneous; Adolescent; Adult; Antibodies, Antiphospholipid; Antiphospholipid Syndrome; B

2018